MYGN

Business Context and Reporting Period

Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2001
Business Overview: Myriad is a fully integrated biopharmaceutical company focused on two primary segments: Research (gene discovery, drug target identification, and therapeutic development) and Predictive Medicine (testing for disease predisposition). The company operates through subsidiaries Myriad Pharmaceuticals, Inc. and Myriad Genetic Laboratories, Inc.

Key Financial Metrics

Segment Performance (Six Months Ended Dec 31, 2001):

• Research Revenue: $14.78 million (Decrease of 6% vs. prior year).
• Predictive Medicine Revenue: $11.89 million (Increase of 69% vs. prior year).

Material Changes vs. Prior Period

• Revenue Mix Shift: While total revenue increased by 17% for the six-month period, the composition shifted significantly. Research revenue declined due to a strategic pivot toward internal drug development and scientific outsourcing to Myriad Proteomics, Inc. Conversely, Predictive Medicine revenue surged 69% driven by increased sales efforts and wider medical acceptance.
• Expense Growth: Selling, General, and Administrative (SG&A) expenses rose 46% year-over-year for the six-month period. This was primarily due to the launch of the MELARIS product and a near-doubling of the sales force (from 43 to 100 employees).
• Operating Cash Flow: Net cash used in operating activities increased to $13.4 million for the six months ended Dec 31, 2001, compared to $8.4 million in the prior year. This was driven by a $10.1 million decrease in deferred revenue as collaborative payments were recognized as revenue.
• Investing Activities: The company generated $28.0 million in cash from investing activities, primarily due to the net sale of marketable investment securities and a shift from securities to cash equivalents.

Outlook, Risks, and Management Commentary

• Strategic Partnerships: In December 2001, Myriad entered an exclusive sales and distribution agreement with Laboratory Corporation of America Holdings (LabCorp) for its four predictive medicine products in the U.S. Additionally, the research phase of a long-standing collaboration with Bayer Corporation concluded, though the company remains entitled to milestone payments and royalties.
• Future Losses: Management expects to incur losses for at least the next several years due to the expansion of R&D, drug discovery, clinical activities, and the costs of launching new predictive medicine products.
• Liquidity: As of December 31, 2001, the company held approximately $134 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least the next two years. A shelf registration statement for up to $250 million in securities was declared effective in November 2001.
• Risks: Key risks include the inability to achieve commercial success for new products, delays in clinical trials, dependence on pharmaceutical collaborations, and the need for substantial future capital to fund development and patent enforcement.

Investor Verification Checklist

• Deferred Revenue Recognition: Verify the sustainability of revenue recognition given the $10.1 million drawdown in deferred revenue during the period.
• Sales Force ROI: Assess whether the 133% increase in sales personnel (to 100 employees) will yield proportional long-term revenue growth in the predictive medicine segment.
• LabCorp Partnership Impact: Monitor the initial performance of the exclusive distribution agreement with LabCorp announced in December 2001.
• Bayer Collaboration Transition: Confirm the timing and magnitude of expected milestone payments and royalties following the conclusion of the research phase with Bayer.
• Cash Burn Rate: Track the rate of cash consumption against the $134 million liquidity position to validate the "two-year runway" assertion.